In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension

[1] Baliga RS(2011)New perspectives for the treatment of pulmonary hypertension Br J Pharmacol 163 125-140

[2] MacAllister RJ(2013)Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 62 D34-D41

[3] Hobbs AJ(2004)Evaluation of pulmonary arterial hypertension Curr Opin Cardiol 19 575-581

[4] Simonneau G(2011)Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil Drugs Today (Barc) 47 145-156

[5] Gatzoulis MA(2009)Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2493-2537

[6] Adatia I(2004)Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 13 S-24 S

[7] Celermajer D(2011)Treatment of pulmonary arterial hypertension with targeted therapies Nat Rev Cardiol 8 526-538

[8] Denton C(2012)Inflammation in pulmonary arterial hypertension Chest 141 210-221

[9] Ghofrani A(2011)Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead Int J Clin Pract Suppl (169) 8-10

[10] Gomez Sanchez MA(1996)Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group N Engl J Med 335 609-616

[1] Baliga RS(2011)New perspectives for the treatment of pulmonary hypertension Br J Pharmacol 163 125-140

[2] MacAllister RJ(2013)Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 62 D34-D41

[3] Hobbs AJ(2004)Evaluation of pulmonary arterial hypertension Curr Opin Cardiol 19 575-581

[4] Simonneau G(2011)Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil Drugs Today (Barc) 47 145-156

[5] Gatzoulis MA(2009)Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2493-2537

[6] Adatia I(2004)Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 13 S-24 S

[7] Celermajer D(2011)Treatment of pulmonary arterial hypertension with targeted therapies Nat Rev Cardiol 8 526-538

[8] Denton C(2012)Inflammation in pulmonary arterial hypertension Chest 141 210-221

[9] Ghofrani A(2011)Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead Int J Clin Pract Suppl (169) 8-10

[10] Gomez Sanchez MA(1996)Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group N Engl J Med 335 609-616